Vericel Corp Ord
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.62 billion
- Book Value:
- Revenue TTM:
- $178.18 million
- Operating Margin TTM:
- Gross Profit TTM:
- $109.79 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Vericel Corp Ord had its IPO on 1997-02-04 under the ticker symbol VCEL.
The company operates in the Healthcare sector and Biotechnology industry. Vericel Corp Ord has a staff strength of 305 employees.
Shares of Vericel Corp Ord opened at $34.07 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $34.06 - $36.87, and closed at $36.52.
This is a +7.22% increase from the previous day's closing price.
A total volume of 565,550 shares were traded at the close of the day’s session.
In the last one week, shares of Vericel Corp Ord have increased by +7.79%.
Vericel Corp Ord's Key Ratios
Vericel Corp Ord has a market cap of $1.62 billion, indicating a price to book ratio of 6.3809 and a price to sales ratio of 6.8909.
In the last 12-months Vericel Corp Ord’s revenue was $178.18 million with a gross profit of $109.79 million and an EBITDA of $-10459000. The EBITDA ratio measures Vericel Corp Ord's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Vericel Corp Ord’s operating margin was -8.33% while its return on assets stood at -3.34% with a return of equity of -7.05%.
In Q2, Vericel Corp Ord’s quarterly earnings growth was a positive 34.3% while revenue growth was a positive 24%.
Vericel Corp Ord’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.27 per share while it has a forward price to earnings multiple of 370.3704 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vericel Corp Ord’s profitability.
Vericel Corp Ord stock is trading at a EV to sales ratio of 7.2466 and a EV to EBITDA ratio of -70.3055. Its price to sales ratio in the trailing 12-months stood at 6.8909.
Vericel Corp Ord stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $310.71 million
- Total Liabilities
- $35.61 million
- Operating Cash Flow
- Capital Expenditure
- $4.20 million
- Dividend Payout Ratio
Vericel Corp Ord ended 2023 with $310.71 million in total assets and $0 in total liabilities. Its intangible assets were valued at $310.71 million while shareholder equity stood at $198.93 million.
Vericel Corp Ord ended 2023 with $0 in deferred long-term liabilities, $35.61 million in other current liabilities, 612059000.00 in common stock, $-412510000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $43.02 million and cash and short-term investments were $97.83 million. The company’s total short-term debt was $7,218,000 while long-term debt stood at $0.
Vericel Corp Ord’s total current assets stands at $182.87 million while long-term investments were $20.99 million and short-term investments were $54.81 million. Its net receivables were $38.32 million compared to accounts payable of $14.40 million and inventory worth $13.88 million.
In 2023, Vericel Corp Ord's operating cash flow was $-2408000.00 while its capital expenditure stood at $4.20 million.
Comparatively, Vericel Corp Ord paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Vericel Corp Ord stock is currently trading at $36.52 per share. It touched a 52-week high of $39.9 and a 52-week low of $39.9. Analysts tracking the stock have a 12-month average target price of $41.
Its 50-day moving average was $34.77 and 200-day moving average was $30.92 The short ratio stood at 12.35 indicating a short percent outstanding of 0%.
Around 81.5% of the company’s stock are held by insiders while 10894.4% are held by institutions.
Frequently Asked Questions About Vericel Corp Ord
Similar Industry Stocks (Biotechnology)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.